These 20 women are 2018's Fiercest in the life sciences industry.
Read 2018's Fiercest Women in Life Sciences report!
Of 31 drugs the Chinese government listed for a pilot bidding program, multinational pharmas landed only two contracts.
The deal will make Takeda "a more competitive, agile, highly profitable, and therefore more resilient company," said CEO Christophe Weber.
Though managing director Dilip Shanghvi tried to allay investors' concerns, a couple of key questions remain unanswered.
A Chinese maker of heparin and APIs for oncology and other drugs is investing nearly $150 million as it targets innovative drugs for China.
Litigation is growing over tainted blood pressure medications with a class-action lawsuit now filed in Florida against Walmart and three drug companies that…
The Justice Department will no longer pursue a whistleblower case against Gilead for using an unapproved API in some HIV drugs.
A Chinese researcher claims is the world's first gene-edited babies; Takeda's Shire deal faces last-minute drama; Celltrion wins first Rituxan biosim…
European regulators are banning heparin from a Chinese facility after finding contamination risks with its production of the anticoagulant.
Mylan has found a valsartan API it made in India contains impurities, leading it and customer Teva to recall more than 60 lots of products.
Citing high risks, Kunio Takeda, the drugmaker's leader from 1993 to 2009, said he doesn't support the Shire acquisition.